A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers

GLS4 is a novel inhibitor of the hepatitis B virus (HBV) capsid assembly with inhibitory activities against nucleot(s)ide-resistant HBV strains. This study investigated the pharmacokinetics, safety, and tolerability of GLS4 and the effects of food and ritonavir in healthy adults. GLS4 was administer...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Antimicrobial agents and chemotherapy 2019-12, Vol.64 (1)
Hauptverfasser:	Zhao, Nan, Jia, Bo, Zhao, Hong, Xu, Junyu, Sheng, Xiaoyan, Luo, Lin, Huang, Zhangma, Wang, Xingan, Ren, Qingyun, Zhang, Yingjun, Zhao, Xia, Cui, Yimin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!